Novo Nordisk announced new partnerships with Hims & Hers Health, LifeMD, and Ro to expand access to authentic, FDA-approved Wegovy® (semaglutide) through a streamlined direct-to-patient model. Patients can now obtain Wegovy® via NovoCare® Pharmacy for $499 per month, with prescription fulfillment handled by CenterWell Pharmacy. The move comes as demand for GLP-1 weight loss treatments continues to grow, with Wegovy® now supporting nearly 1.5 million patients in the U.S.

Discover how Nestlé Health Science is addressing the growing GLP-1 medication market with their new nutrition platform and Vital Pursuit food line, designed to support weight management and wellness.

Discover the latest on Peloton's leadership changes and workforce adjustments, including CEO Barry McCarthy's transition to a strategic advisor and a 15% reduction in staff due to decreased demand for fitness equipment post-pandemic.

Explore the latest study on obesity treatments in the Obesity journal, analyzing the effectiveness of traditional diets, GLP-1 receptor agonists like semaglutide and tirzepatide, and surgical options such as Roux-en-Y gastric bypass. Learn how these interventions impact weight-loss plateaus.